Volume 2.16 | Apr 29

Mammary Cell News 2.16 April 29, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers
Researchers characterized ALDH1 expression in 24 types of normal tissues and a large collection of epithelial tumor specimens by immunohistochemical staining. [PLoS ONE]



Complimentary Webinar Presented by STEMCELL Technologies Assays for Mammary Epithelial Stem Cells and Progenitors

Speaker: Dr. John Stingl, PhD, Cancer Research UK Cambridge Research Institute

Tuesday, May 11th at 3PM BST
Ideal for participants in Europe

Tuesday, May 11th at 9AM PST/12PM EST
Ideal for participants in the Americas

Wednesday, May 12th at 1PM Singapore Time
Ideal for participants in Asia-Pacific


German Study is First to Clearly Link Mutations in the RAD51C Gene to Breast and Ovarian Cancer
The gene newly identified as causing breast and ovarian cancer in familial cases is designated RAD51C. It is, like BRCA1 and BRCA2, essential for DNA repair within cells. [Press release from Medical News Today discussing online prepublication in Nature Genetics]

Resetting Biological Clock May Help Prevent Breast Cancer
Investigators have discovered that a form of the dietary trace element selenium can help reset a cell’s “biological clock” when it is disrupted by a chemical cancer-causing agent. [Press release from Medical News Today discussing online prepublication in Cancer Prevention Research]

Cell Study Finds Receptor Can Fight Tamoxifen-Resistant Breast Cancer Cells
The study built on the recent discovery that farnesoid X receptor (FXR), a nuclear receptor found mainly in the liver, is found in breast cancer tissue. [EurekAlert! Press Release]

Routine Breast Cancer Biopsy Might Predict Lymph Node Cancer Spread
Researchers say that they have clues to molecular markers on breast tumors that may predict which cancers will metastasize to the lymph node system. [Georgetown Lombardi Comprehensive Cancer Center Press Release]

Watch Procedure Now  
Use EpiCult-B® to Culture and Characterize
Human Mammary Epithelial Progenitors

by STEMCELL Technologies



The Eyes Absent Phosphatase-Transactivator Proteins Promote Proliferation, Transformation, Migration, and Invasion of Tumor Cells
The Eyes Absent (EYA) proteins are known to be expressed at elevated levels in ovarian and breast cancers. Here, researchers show that the tyrosine phosphatase activity of the EYAs promotes tumor cell migration, invasion, and transformation. [Oncogene]

Essential Role of PI3-Kinase Pathway in p53-Mediated Transcription: Implications in Cancer Chemotherapy
Here, researchers report that p53-mediated transcription is inhibited by pharmacological inhibitors and a dominant-negative mutant of PI3-kinase, and this inhibition was relieved by a constitutively active mutant of PI3-kinase. [Oncogene]

Disulfiram Treatment Facilitates Phosphoinositide 3-Kinase Inhibition in Human Breast Cancer Cells In Vitro and In Vivo
In this study, researchers showed that in the presence of copper, disulfiram, a clinically used antialcoholism drug, could potently inhibit breast cancer cell growth regardless of the PIK3CA status. [Cancer Res]

Spontaneous Feline Mammary Intraepithelial Lesions as a Model for Human Estrogen Receptor- and Progesterone Receptor-Negative Breast Lesions
The purpose of this study was to characterize the histologic and molecular features of feline mammary intraepithelial lesions and compare them with those in women. [BMC Cancer]

Risk of Breast and Prostate Cancer is Not Associated with Increased Homozygosity in Outbred Populations
To examine whether homozygosity is associated with breast or prostate cancer risk, researchers analysed 500K single-nucleotide polymorphism data from two genome-wide association studies conducted by the Cancer Genetics Markers of Susceptibility initiatives. [Eur J Hum Genet]

Docosahexaenoic Acid Induces Apoptosis in MCF-7 Cells In Vitro and In Vivo via Reactive Oxygen Species Formation and Caspase 8 Activation

Using athymic nude mice as an in vivo model, researchers found that feeding animals the 5% fish oil-supplemented diet for 6 weeks significantly reduces the growth of MCF-7 human breast cancer cells in vivo through inhibition of cancer cell proliferation as well as promotion of cell death. [PLoS ONE]


Phase II Parallel Group Study Showing Comparable Efficacy Between Premenopausal Metastatic Breast Cancer Patients Treated With Letrozole Plus Goserelin and Postmenopausal Patients Treated With Letrozole Alone As First-Line Hormone Therapy
Goserelin and letrozole in premenopausal patients can result in clinical outcomes comparable to those obtained by letrozole alone in postmenopausal patients with metastatic breast cancer. [J Clin Oncol]

Effect of Zoledronic Acid on Disseminated Tumour Cells in Women with Locally Advanced Breast Cancer: An Open Label, Randomised, Phase II Trial

The aim of this study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer. [Lancet Oncol]

Presence of an In Situ Component is Associated with Reduced Biological Aggressiveness of Size-Matched Invasive Breast Cancer
Researchers analysed data from 1355 breast cancer patients. End points were defined by the association of invasive ductal carcinoma (with or without ductal carcinoma in situ) with grade, nodal status, Ki-67, and ER/HER2. [Br J Cancer]


Bionovo Announces Patent Issuance for Bezielle(R) (BZL101) for Metastatic Breast Cancer
Bionovo, Inc. announced that the US Patent and Trademark Office (USPTO) has issued a patent covering a method of using Bionovo’s proprietary drug candidate Bezielle(R) (BZL101) for the treatment of metastatic breast cancer. [Bionovo, Inc. Press Release]

Manhattan Scientifics’ Technology Able to Detect Breast Cancer Three Years Earlier than Mammogram
Manhattan Scientifics, Inc. announced that its “early cancer detection” technology, developed by Edward R. Flynn, Ph.D. is expected to identify breast cancer three years earlier than the current gold standard mammogram test. [Manhattan Scientifics, Inc. Press Release]

U.S. to WellPoint: Stop Dropping Breast Cancer Patients
Department of Health and Human Services Secretary Kathleen Sebelius has called on health insurer WellPoint to stop dropping coverage for patients recently diagnosed with breast cancer, calling the practice “deplorable.” [Reuters]

Aragon Pharmaceuticals Secures $22 Million in Series B Financing
Aragon Pharmaceuticals Inc. announced that it has secured $22 million in Series B financing. New investor Aisling Capital participated in the financing along with existing investors OrbiMed Advisors and The Column Group. [FierceBiotech]


Michigan Senate Passes Stem Cell Regulation Package
The Republican-led Senate passed a package of regulations critics say will place a chill on stem cell research in violation of the Michigan Constitution. [Michigan Senate, United States]

Gubernatorial Candidates Talk Ways to Boost Bioscience
Five gubernatorial candidates offered their prescriptions for creating a healthier climate for Minnesota’s biotech industry that included lower taxes, higher government spending, and faith in science over ideology. [Minnesota, United States]

Request for Information (RFI): Priorities for the NIH Adherence Research Network (NOT-OD-10-078) [National Institutes of Health, United States]

Waivers for Conflicts of Interest for the May 7, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Food and Drug Administration, United States]

FDA Announces Draft Revised Guidance on Transparency and Advisory Committees [Food and Drug Administration, United States]

Draft Guidance for the Public, Food and Drug Administration Advisory Committee Members, and Food and Drug Administration Staff: Public Availability of Advisory Committee Members’ Financial Interest Information and Waivers; Availability (Docket No. FDA-2002-D-0094) [Food and Drug Administration, United States]


IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

American Society of Clinical Oncology (ASCO) Annual Meeting 2010
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom


Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us